Benztropine Does Not Help Restless Legs Syndrome
No, benztropine should not be used for restless legs syndrome (RLS). Benztropine is an anticholinergic medication FDA-approved only for Parkinson's disease and drug-induced extrapyramidal disorders 1, and it has no role in RLS treatment according to the most recent 2025 American Academy of Sleep Medicine guidelines [2-2].
Why Benztropine Is Not Appropriate for RLS
Wrong Mechanism and Indication
Benztropine works as an anticholinergic agent to counteract dopaminergic imbalance in Parkinson's disease and neuroleptic-induced movement disorders 1. RLS has a completely different pathophysiology involving brain iron deficiency and dopaminergic dysfunction that requires different therapeutic approaches 3.
Anticholinergics May Worsen RLS
Anticholinergic medications like benztropine can potentially worsen RLS symptoms or interfere with sleep quality. The evidence shows that certain medication classes (antidepressants, antihistamines with anticholinergic properties, dopamine antagonists) should be reduced or discontinued because they induce or exacerbate RLS symptoms 4.
What Actually Works for RLS
Based on the 2025 AASM guidelines, here is the evidence-based treatment algorithm:
First-Line Treatments (Strong Recommendations)
- Gabapentin - strong recommendation, moderate certainty 2
- Pregabalin - strong recommendation, moderate certainty 2
- IV ferric carboxymaltose - strong recommendation for patients with appropriate iron status 2
Second-Line Options (Conditional Recommendations)
- Oral ferrous sulfate - for patients with low iron stores 2
- Dipyridamole - conditional recommendation 2
- Extended-release oxycodone and other opioids - conditional recommendation 2
Dopamine Agonists: Use With Caution
The 2025 guidelines represent a major shift: dopamine agonists (pramipexole, ropinirole, rotigotine) are now suggested AGAINST for standard use due to the significant risk of augmentation with long-term use [2-2]. They may only be considered for short-term use in patients who prioritize immediate symptom relief over long-term adverse effects.
Medications to Avoid
The AASM specifically recommends against: bupropion, carbamazepine, clonazepam, valproic acid, and strongly recommends against cabergoline [2-2].
Clinical Pitfall
The critical error would be confusing benztropine's use in Parkinson's disease with potential benefit in RLS. While both conditions involve movement and dopamine pathways, they are fundamentally different disorders requiring opposite therapeutic approaches. Benztropine has no evidence base for RLS and could potentially interfere with effective treatment.